Frights, Fangs, and Healthcare Nightmares in Winning Halloween Haikus

What’s scarier than ghosts and goblins? How about measles, unaffordable dental care, and an insurance claim denied by artificial intelligence? Nearly 80 healthcare-themed haikus crept into our inbox this Halloween season. Meet the winners of KFF Health News’ eighth annual Halloween haiku contest below. Follow KFF Health News’ social media accounts (X, Instagram, and Facebook)…

Read More

Medicare Part D Premiums and Cost Sharing in 2027

Medicare Part D is a voluntary outpatient prescription drug benefit for people with Medicare provided through private plans, including stand-alone prescription drug plans and Medicare Advantage plans that offer drug coverage. This analysis provides an overview of Medicare Part D premiums and cost sharing in 2027 and key trends over time.

Read More

The Average Monthly Premium for Medicare Part D Stand-Alone Plans Is Projected to Increase by 50% From $34 to $51 in 2027 Unless Enrollees Switch to Lower-Cost Plans 

A new KFF analysis finds that the average monthly premium for Medicare Part D coverage in stand-alone prescription drug plans (PDPs) will increase to $51 in 2027, up 50% from $34 in 2026, if current enrollees don’t switch into lower-premium plans during open enrollment, which runs through December 7.  

Read More

2026 Mid-terms: Voting for the Future

By MIKE MAGEE This week, New York Times political columnist, Linda Kindler reflected on “How Silicon Valley Stole the Future.” Signaling that this wasn’t simply another article on the binary choices of an AI world – or as she put it “either a world in which A.I. has eliminated all jobs, unleashed bioengineered viruses and…

Read More

BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting…

Read More